These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 28910345)

  • 1. Circulating mRNAs and miRNAs as candidate markers for the diagnosis and prognosis of prostate cancer.
    Souza MF; Kuasne H; Barros-Filho MC; Cilião HL; Marchi FA; Fuganti PE; Paschoal AR; Rogatto SR; Cólus IMS
    PLoS One; 2017; 12(9):e0184094. PubMed ID: 28910345
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma miRNAs as biomarkers to identify patients with castration-resistant metastatic prostate cancer.
    Watahiki A; Macfarlane RJ; Gleave ME; Crea F; Wang Y; Helgason CD; Chi KN
    Int J Mol Sci; 2013 Apr; 14(4):7757-70. PubMed ID: 23574937
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating mRNA signature as a marker for high-risk prostate cancer.
    Souza MF; Kuasne H; Barros-Filho MC; Cilião HL; Marchi FA; Fuganti PE; Rogatto SR; Cólus IMS
    Carcinogenesis; 2020 Apr; 41(2):139-145. PubMed ID: 31305891
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Functional roles and potential clinical application of miRNA-345-5p in prostate cancer.
    Tinay I; Tan M; Gui B; Werner L; Kibel AS; Jia L
    Prostate; 2018 Sep; 78(12):927-937. PubMed ID: 29748958
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MiR-139-5p is Increased in the Peripheral Blood of Patients with Prostate Cancer.
    Pang C; Liu M; Fang W; Guo J; Zhang Z; Wu P; Zhang Y; Wang J
    Cell Physiol Biochem; 2016; 39(3):1111-7. PubMed ID: 27562849
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating microRNAs and treatment response in the Phase II SWOG S0925 study for patients with new metastatic hormone-sensitive prostate cancer.
    Cheng HH; Plets M; Li H; Higano CS; Tangen CM; Agarwal N; Vogelzang NJ; Hussain M; Thompson IM; Tewari M; Yu EY
    Prostate; 2018 Feb; 78(2):121-127. PubMed ID: 29105802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential blood-based diagnosis between benign prostatic hyperplasia and prostate cancer: miRNA as source for biomarkers independent of PSA level, Gleason score, or TNM status.
    Leidinger P; Hart M; Backes C; Rheinheimer S; Keck B; Wullich B; Keller A; Meese E
    Tumour Biol; 2016 Aug; 37(8):10177-85. PubMed ID: 26831660
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Five microRNAs in serum as potential biomarkers for prostate cancer risk assessment and therapeutic intervention.
    Guo X; Han T; Hu P; Guo X; Zhu C; Wang Y; Chang S
    Int Urol Nephrol; 2018 Dec; 50(12):2193-2200. PubMed ID: 30324582
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating miRNAs as Biomarkers for Prostate Cancer Diagnosis in Subjects with Benign Prostatic Hyperplasia.
    Jin W; Fei X; Wang X; Chen F; Song Y
    J Immunol Res; 2020; 2020():5873056. PubMed ID: 32455140
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic and prognostic value of serum miR-15a and miR-16-1 expression among egyptian patients with prostate cancer.
    Zidan HE; Abdul-Maksoud RS; Elsayed WSH; Desoky EAM
    IUBMB Life; 2018 May; 70(5):437-444. PubMed ID: 29522280
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An elevated serum miR-141 level in patients with bone-metastatic prostate cancer is correlated with more bone lesions.
    Zhang HL; Qin XJ; Cao DL; Zhu Y; Yao XD; Zhang SL; Dai B; Ye DW
    Asian J Androl; 2013 Mar; 15(2):231-5. PubMed ID: 23377530
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combinations of serum prostate-specific antigen and plasma expression levels of let-7c, miR-30c, miR-141, and miR-375 as potential better diagnostic biomarkers for prostate cancer.
    Kachakova D; Mitkova A; Popov E; Popov I; Vlahova A; Dikov T; Christova S; Mitev V; Slavov C; Kaneva R
    DNA Cell Biol; 2015 Mar; 34(3):189-200. PubMed ID: 25521481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery and Validation of Serum MicroRNAs as Early Diagnostic Biomarkers for Prostate Cancer in Chinese Population.
    Lyu J; Zhao L; Wang F; Ji J; Cao Z; Xu H; Shi X; Zhu Y; Zhang C; Guo F; Yang B; Sun Y
    Biomed Res Int; 2019; 2019():9306803. PubMed ID: 31534967
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic performance of expression of PCA3, Hepsin and miR biomarkers inejaculate in combination with serum PSA for the detection of prostate cancer.
    Roberts MJ; Chow CW; Schirra HJ; Richards R; Buck M; Selth LA; Doi SA; Samaratunga H; Perry-Keene J; Payton D; Yaxley J; Lavin MF; Gardiner RA
    Prostate; 2015 Apr; 75(5):539-49. PubMed ID: 25597828
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Associations of Prostate-Specific Antigen, Prostate Carcinoma Tissue Gleason Score, and Androgen Receptor Expression with Bone Metastasis in Patients with Prostate Carcinoma.
    Chen Y; Lin Y; Nie P; Jiang W; Liu Y; Yuan R; Li M; Zhao S; Lin H; Li P; Zhang J; Hu Z; Xu J; Zhu X
    Med Sci Monit; 2017 Apr; 23():1768-1774. PubMed ID: 28400549
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum miR-200c is a novel prognostic and metastasis-predictive biomarker in patients with colorectal cancer.
    Toiyama Y; Hur K; Tanaka K; Inoue Y; Kusunoki M; Boland CR; Goel A
    Ann Surg; 2014 Apr; 259(4):735-43. PubMed ID: 23982750
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic Role of Serum Free-to-Total Prostate Specific Antigen (PSA) Ratio in Prostate Cancer with Serum Total Concentration of PSA below 4 ng/mL.
    Chang CC; Lee YC; Tsai HW; Yii SC; Yen TH; Chu FY
    Asian Pac J Cancer Prev; 2015; 16(13):5261-4. PubMed ID: 26225663
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating microRNAs as potential diagnostic biomarkers and therapeutic targets in prostate cancer: Current status and future perspectives.
    Movahedpour A; Ahmadi N; Ghasemi Y; Savardashtaki A; Shabaninejad Z
    J Cell Biochem; 2019 Oct; 120(10):16316-16329. PubMed ID: 31257636
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of prostate-specific antigen RNA before and after radical retropubic prostatectomy and transurethral resection of the prostate using "Light-Cycler"-based quantitative real-time polymerase chain reaction.
    Straub B; Müller M; Krause H; Schrader M; Goessl C; Heicappell R; Miller K
    Urology; 2001 Nov; 58(5):815-20. PubMed ID: 11711374
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MiR-145 detection in urinary extracellular vesicles increase diagnostic efficiency of prostate cancer based on hydrostatic filtration dialysis method.
    Xu Y; Qin S; An T; Tang Y; Huang Y; Zheng L
    Prostate; 2017 Jul; 77(10):1167-1175. PubMed ID: 28617988
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.